Your session is about to expire
← Back to Search
NK Cell Therapy
aNK (NK-92) + N-803 for Merkel Cell Carcinoma
Phase 2
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
Summary
This trial tests a combination of immune cells and a boosting drug in patients with advanced Merkel Cell Carcinoma. The treatment aims to enhance the body's immune response to fight the cancer more effectively. Recent advancements have changed the treatment landscape for patients with advanced Merkel Cell Carcinoma.
Eligible Conditions
- Merkel Cell Carcinoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Overall Response Rate
Overall survival
Quality of life assessment
+2 moreOther study objectives
Exploratory Genomic, Transcriptomic, and Proteomic Analysis
Trial Design
2Treatment groups
Experimental Treatment
Group I: aNK (NK-92) + N-803Experimental Treatment1 Intervention
aNK (activated NK-92, formerly Neukoplast) and N-803
Group II: aNK (NK-92)Experimental Treatment1 Intervention
aNK (activated NK-92, formerly Neukoplast)
Find a Location
Who is running the clinical trial?
ImmunityBio, Inc.Lead Sponsor
66 Previous Clinical Trials
4,750 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger